Brief: Gracell Biotechnologies Signs Exclusive License Agreement With Futuregen Biopharm
16/08/2021 13:37
Aug 16 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES SIGNS EXCLUSIVE LICENSE AGREEMENT
WITH
FUTUREGEN BIOPHARM TO DEVELOP ENGINEERED IMMUNE CELL THERAPIES
TARGETING CLAUDIN 18.2 IN SOLID TUMORS
* GRACELL - FUTUREGEN WILL RECEIVE AN UPFRONT PAYMENT AND
WILL BE
ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS BASED ON ACHIEVEMENT OF
MILESTONES
Source text for Eikon: ID:nPnGT6pMa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27